Miguel Alcaide
Overview
Explore the profile of Miguel Alcaide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glueck V, Grimm C, Postl M, Brueffer C, Segui N, Alcaide M, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075633
Background/objectives: The surgeon's subjective intraoperative evaluation is the standard of care to assess postoperative residual disease (RD) in advanced epithelial ovarian cancer (EOC). We investigated the feasibility of ctDNA as...
2.
Elliott M, Howarth K, Main S, Fuentes Antras J, Echelard P, Dou A, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39785866
Purpose: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy in early breast cancer (EBC) is highly prognostic of disease recurrence. Current ctDNA assays, mainly targeting single nucleotide variants...
3.
Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, et al.
Br J Haematol
. 2024 Sep;
205(5):2067-2071.
PMID: 39267295
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial...
4.
Meng P, Dalal H, Chen Y, Brueffer C, Gladchuk S, Alcaide M, et al.
NPJ Breast Cancer
. 2024 Feb;
10(1):14.
PMID: 38374091
HER2/ERBB2 evaluation is necessary for treatment decision-making in breast cancer (BC), however current methods have limitations and considerable variability exists. DNA copy number (CN) evaluation by droplet digital PCR (ddPCR)...
5.
Coyle K, Hillman T, Cheung M, Grande B, Bushell K, Arthur S, et al.
Blood Adv
. 2022 Mar;
6(11):3404-3409.
PMID: 35359007
No abstract available.
6.
Lavoie J, Alcaide M, Fisher R, Seckl M, Morin R, Tinker A
JCO Precis Oncol
. 2022 Feb;
1:1-6.
PMID: 35172520
No abstract available.
7.
Morin J, Royle T, Zhang H, Speller C, Alcaide M, Morin R, et al.
Sci Rep
. 2021 Nov;
11(1):21160.
PMID: 34759290
To gain insight into pre-contact Coast Salish fishing practices, we used new palaeogenetic analytical techniques to assign sex identifications to salmonid bones from four archaeological sites in Burrard Inlet (Tsleil-Waut),...
8.
Alcaide M, Cheung M, Hillman J, Rassekh S, Deyell R, Batist G, et al.
Sci Rep
. 2020 Jul;
10(1):12564.
PMID: 32724107
Cell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can be...
9.
Rushton C, Arthur S, Alcaide M, Cheung M, Jiang A, Coyle K, et al.
Blood Adv
. 2020 Jun;
4(13):2886-2898.
PMID: 32589730
Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extremely poor if R-CHOP fails. To identify...
10.
Pararajalingam P, Coyle K, Arthur S, Thomas N, Alcaide M, Meissner B, et al.
Blood
. 2020 Mar;
136(5):572-584.
PMID: 32160292
Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standard therapies. The genetic drivers of this cancer have not been firmly established, and the...